Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vertebra

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Vertebra. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2010-019263-11 Sponsor Protocol Number: LTS11298 Start Date*: 2010-07-08
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A multicenter uncontrolled extension study evaluating the long term safety and efficacy of SAR153191 in patients with Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Prematurely Ended) LT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005575-41 Sponsor Protocol Number: CAIN457F2320 Start Date*: 2015-03-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tole...
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) AT (Completed) NL (Completed) FI (Completed) NO (Completed) DK (Completed) GB (Completed) ES (Completed) SK (Completed) BG (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017443-34 Sponsor Protocol Number: NA22823 Start Date*: 2010-11-01
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab v...
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016068-35 Sponsor Protocol Number: DRI11073 Start Date*: 2010-02-19
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) LT (Completed) AT (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011591-30 Sponsor Protocol Number: CAIN457A2209E1 Start Date*: 2010-09-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis
    Medical condition: Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001089-40 Sponsor Protocol Number: CAIN457F2305E1 Start Date*: 2013-08-27
    Sponsor Name:Novartis Farma SpA
    Full Title: An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis
    Medical condition: Ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) DE (Completed) NL (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001090-24 Sponsor Protocol Number: CAIN457F2314 Start Date*: 2014-01-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to...
    Medical condition: Ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) PT (Completed) GR (Completed) GB (Completed) BE (Completed) NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004229-40 Sponsor Protocol Number: 112008 Start Date*: 2009-03-09
    Sponsor Name:Imperial College London
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003096-39 Sponsor Protocol Number: 0881A3-4458-EU Start Date*: 2009-07-29
    Sponsor Name:WYETH LEDERLE
    Full Title: Effects of Etanercept on Endothelial Function and Carotid Intima-Media Thickness In Patients With Active Ankylosing Spondylitis: a 52-Weeks, Randomized, Double Blind, Placebo-Controlled Study
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004532-18 Sponsor Protocol Number: M10-239 Start Date*: 2014-11-12
    Sponsor Name:Abbott
    Full Title: A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000087-25 Sponsor Protocol Number: A090913 Start Date*: 2007-10-22
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003358-27 Sponsor Protocol Number: HUM06-037 Start Date*: 2008-05-02
    Sponsor Name:Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
    Full Title: Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab
    Medical condition: Juvenile ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    10 10002556 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016587-36 Sponsor Protocol Number: P06451 Start Date*: 2010-03-15
    Sponsor Name:Schering Plough, S.A
    Full Title: Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®)
    Medical condition: Espondilitis anquilosante
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017309-12 Sponsor Protocol Number: GRE-2009-01 Start Date*: 2010-02-18
    Sponsor Name:FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER)
    Full Title: Evaluación de la respuesta a etoricoxib en pacientes con Espondilitis Anquilosante (EA) e inadecuada respuesta > o = a 2 AINES
    Medical condition: Espondilitis Anquilosante
    Disease: Version SOC Term Classification Code Term Level
    9 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004939-23 Sponsor Protocol Number: PHRI12-ED-COMARIS Start Date*: 2013-07-16
    Sponsor Name:CHRU de TOURS
    Full Title: Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la Réduction de l’Immunisation au cours de la Spondylarthrite ankylosante
    Medical condition: Cette étude portera sur une population avec une spondylarthrite ankylosante (SA) active nécessitant un traitement par adalimumab
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007637-39 Sponsor Protocol Number: ENRADAS-01 Start Date*: 2008-12-17
    Sponsor Name:Charité - Campus Mitte
    Full Title: Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2
    Medical condition: Ankylosing spondylitis patients (according to mod. New York criteria) who have have active disease at inclusion defined as BASDAI question 2 (related to back pain) >= 4 (VAS, range 0-10) without NS...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003932-11 Sponsor Protocol Number: I1F-MC-RHBV Start Date*: 2016-04-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with ...
    Medical condition: Radiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10041672 Spondylitis ankylosing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-001684-77 Sponsor Protocol Number: 1407-0003 Start Date*: 2020-12-07
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A 12-weeks Phase II, randomized, double-blind, placebocontrolled, parallel-group, proof-of-concept trial of BI 730357 in patients with active ankylosing spondylitis
    Medical condition: axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10041672 Spondylitis ankylosing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004108-37 Sponsor Protocol Number: CC-99677-AS-001 Start Date*: 2021-07-09
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-017488-40 Sponsor Protocol Number: WA22908 Start Date*: 2010-11-01
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, parallel-group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylos...
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) BE (Prematurely Ended) DE (Completed) DK (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 14:44:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA